Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

A Study to Test How a New Long-acting Insulin Works in the Body of Patients With Type 2 Diabetes During Exercise and Prolonged Fasting

Phase 1

Recruiting

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Insulin icodec
Drug: Insulin degludec

First Posted Date: 2024-03-01

Last Posted Date: 2024-04-02

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 30

Registration Number: NCT06288412

Locations: 🇦🇹
Medical University of Graz, Graz, Austria

Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A or Haemophilia B With Inhibitors

Conditions: Haemophilia B
Haemophilia A

Interventions: Drug: Concizumab

First Posted Date: 2024-02-29

Last Posted Date: 2024-08-21

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 23

Registration Number: NCT06285071

Locations: 🇯🇵
Mutsu general hospital, Aomori, Japan
🇯🇵
Novo Nordisk Investigational Site, Toshima, Tokyo, Japan
🇯🇵
Sapporo Tokushukai Hospital_Pediatrics, Hokkaido, Japan

and more 1 locations

A Research Study of a New Medicine (NNC0650-0013) in Healthy Men

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: NNC0650-0013 A
Drug: Placebo

First Posted Date: 2024-02-29

Last Posted Date: 2024-11-19

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 11

Registration Number: NCT06284798

Locations: 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany

Special Use - Results Surveillance on Long-term Use With Wegovy®

Conditions: Obesity

Interventions: Drug: Semaglutide

First Posted Date: 2024-02-28

Last Posted Date: 2024-12-12

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1000

Registration Number: NCT06283667

Locations: 🇯🇵
Osaki citizen hospital, Diabetes and metabolic disease, Osaki-shi, Miyagi, Japan
🇯🇵
Novo Nordisk Investigational Site, Tokyo, Chiyoda City, Japan
🇯🇵
Okazaki City Hospital, Aichi, Japan

and more 29 locations

Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.

Active, not recruiting

Conditions: Obesity

Interventions: Drug: Liraglutide

First Posted Date: 2024-02-28

Last Posted Date: 2024-12-12

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 288

Registration Number: NCT06283641

Locations: 🇨🇳
Changhua Christian Hospital, Changhua City, Taiwan
🇨🇳
HsinChu Municipal MacKay Children's Hospital, Hsinchu City, Taiwan
🇨🇳
HsinChu MacKay Memorial Hospital, Hsinchu City, Taiwan

and more 11 locations

SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in Hungary

Not yet recruiting

Conditions: Type 2 Diabetes

Interventions: Drug: Oral Semaglutide

First Posted Date: 2024-02-21

Last Posted Date: 2024-02-21

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 470

Registration Number: NCT06269120

A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)

Phase 3

Active, not recruiting

Conditions: Type 2 Diabetes

Interventions: Drug: IcoSema
Drug: Insulin glargine

First Posted Date: 2024-02-21

Last Posted Date: 2024-11-19

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 474

Registration Number: NCT06269107

Locations: 🇺🇸
Consano Clinical Research, LLC, Shavano Park, Texas, United States
🇺🇸
TPMG Clinical Research, Newport News, Virginia, United States
🇨🇳
Peking University People's Hospital, Beijing, Beijing, China

and more 89 locations

A Study of How CagriSema Works on Appetite in People With Excess Body Weight

Phase 1

Active, not recruiting

Conditions: Overweight
Obesity

Interventions: Other: No treatment given
Drug: Cagrilintide and Semaglutide
Drug: Placebo

First Posted Date: 2024-02-20

Last Posted Date: 2024-12-11

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 150

Registration Number: NCT06267092

Locations: 🇩🇪
Charité Research Organisation GmbH, Berlin, Germany

A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis

Phase 2

Recruiting

Conditions: Transthyretin Amyloid Cardiomyopathy (ATTR CM)

Interventions: Drug: NNC6019-0001

First Posted Date: 2024-02-15

Last Posted Date: 2024-10-07

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 80

Registration Number: NCT06260709

Locations: 🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸
Cedars-Sinai Medical Center_Los Angeles, Los Angeles, California, United States
🇺🇸
Stanford Hlth Cre-Boswell Clin, Stanford, California, United States

and more 27 locations

Assessing Health-Related Quality of Life and Willingness to Pay for Weight Management in Asia-Pacific by Gender

Completed

Conditions: Overweight
Obesity

Interventions: Other: No treatment is given

First Posted Date: 2024-02-15

Last Posted Date: 2024-02-15

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 3000

Registration Number: NCT06260696

Locations: 🇦🇪
Novo Nordisk Investigational Site, Dubai, United Arab Emirates

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy